{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:22:16Z","timestamp":1785252136846,"version":"3.55.0"},"reference-count":123,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London"},{"name":"National Health Service"},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To identify how refractory disease (or relevant terminology variations) in RA and polyarticular JIA (polyJIA) is defined and establish the key components of such definitions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Searches were undertaken of English-language articles within six medical databases, including manual searching, from January 1998 to March 2020 (PROSPERO: CRD42019127142). Articles were included if they incorporated a definition of refractory disease, or non-response, in RA\/polyJIA, with clear components to the description. Qualitative content analysis was undertaken to describe refractory disease in RA\/polyJIA and classify each component within each definition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 6251 studies screened, 646 met the inclusion criteria; 581 of these applied non-response criteria while 65 provided refractory disease definitions\/descriptions. From the non-response studies, 39 different components included various disease activity measures, emphasizing persistent disease activity and symptoms, despite treatment with one or more biologic DMARD (bDMARD). From papers with clear definitions for refractory disease, 41 components were identified and categorized into three key themes: resistance to multiple drugs with different mechanisms of action, typically two or more bDMARDs; persistence of symptoms and disease activity; and other contributing factors. The most common term used was \u2018refractory\u2019 (80%), while only 16.9% reported explicitly how their definition was generated (e.g. clinical experience or statistical methods).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Refractory disease is defined as resistance to multiple drugs with different mechanisms of action by persistence of physical symptoms and high disease activity, including contributing factors. A clear unifying definition needs implementing, as the plethora of different definitions makes study comparisons and appropriate identification of patients difficult.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keab237","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T12:15:24Z","timestamp":1615378524000},"page":"3540-3552","source":"Crossref","is-referenced-by-count":15,"title":["Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9402-9669","authenticated-orcid":false,"given":"Hema","family":"Chaplin","sequence":"first","affiliation":[{"name":"Health Psychology Section, Institute of Psychiatry, Psychology and Neuroscience, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Health Psychology Section, Institute of Psychiatry, Psychology and Neuroscience, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni","family":"Raz","sequence":"additional","affiliation":[{"name":"Health Psychology Section, Institute of Psychiatry, Psychology and Neuroscience, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Lempp","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-9963","authenticated-orcid":false,"given":"Sam","family":"Norton","sequence":"additional","affiliation":[{"name":"Health Psychology Section, Institute of Psychiatry, Psychology and Neuroscience, London, UK"},{"name":"Centre for Rheumatic Diseases, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"2021080220111619300_keab237-B1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B2","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B3","first-page":"CD007848","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews","volume":"4","author":"Singh","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2021080220111619300_keab237-B4","first-page":"1","article-title":"Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation","volume":"20","author":"Stevenson","year":"2016","journal-title":"Health Technol Assess"},{"key":"2021080220111619300_keab237-B5","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/rheumatology\/kew241","article-title":"Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"55","author":"Druce","year":"2016","journal-title":"Rheumatology"},{"key":"2021080220111619300_keab237-B6","author":"Young","year":"2015"},{"key":"2021080220111619300_keab237-B7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.autrev.2011.04.023","article-title":"Rheumatoid arthritis: what is refractory disease and how to manage it?","volume":"10","author":"Polido-Pereira","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2021080220111619300_keab237-B8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/berh.1999.0057","article-title":"Management of therapy-resistant rheumatoid arthritis","volume":"13","author":"Kroot","year":"1999","journal-title":"Baillieres Best Pract Res Clin Rheumatol"},{"key":"2021080220111619300_keab237-B9","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","article-title":"Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"77","author":"Kearsley-Fleet","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B10"},{"key":"2021080220111619300_keab237-B11","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","article-title":"Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey","volume":"77","author":"Roodenrijs","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B12","first-page":"1135","article-title":"Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need","volume":"57","author":"de Hair","year":"2018","journal-title":"Rheumatology"},{"key":"2021080220111619300_keab237-B13","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1007\/s10067-019-04579-1","article-title":"Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis","volume":"38","author":"Batko","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2021080220111619300_keab237-B14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/rheumatology\/kep458","article-title":"Fibromyalgic rheumatoid arthritis and disease assessment","volume":"49","author":"Pollard","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2021080220111619300_keab237-B15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/rheumatology\/key107","article-title":"Are we failing patients in our assessment of treatment failure?","volume":"58","author":"Nikiphorou","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2021080220111619300_keab237-B16","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/annrheumdis-2017-212862","article-title":"Defining refractory rheumatoid arthritis","volume":"77","author":"Buch","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B17","year":"2017"},{"key":"2021080220111619300_keab237-B18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.amjmed.2005.01.029","article-title":"Infliximab therapy in established rheumatoid arthritis: an observational study","volume":"118","author":"Voulgari","year":"2005","journal-title":"Am J Med"},{"issue":"Suppl 2","key":"2021080220111619300_keab237-B19","first-page":"348","article-title":"THU0151 Comparison between three proposed definitions of difficult-to-treat\/refractory rheumatoid arthritis in a cohort of bDMARD-treated patients","volume":"78","author":"Ometto","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B20","author":"Higgins","year":"2011"},{"key":"2021080220111619300_keab237-B21","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Med"},{"key":"2021080220111619300_keab237-B22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"The use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin Ther"},{"key":"2021080220111619300_keab237-B23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guidelines for the management of rheumatoid arthritis: 2002 update","volume":"46","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2021080220111619300_keab237-B24","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/1529-0131(199809)41:9<1548::AID-ART4>3.0.CO;2-I","article-title":"Combination therapy with biologic agents in rheumatoid arthritis: perils and promise","volume":"41","author":"Kremer","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2021080220111619300_keab237-B25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10067-007-0654-6","article-title":"Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence","volume":"27","author":"Gartlehner","year":"2008","journal-title":"Clin Rheumatol"},{"key":"2021080220111619300_keab237-B26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med"},{"key":"2021080220111619300_keab237-B27","first-page":"181","volume-title":"Compendium for early career researchers in mathematics education","author":"U","year":"2019"},{"key":"2021080220111619300_keab237-B28","first-page":"159","article-title":"Qualitative content analysis","author":"Mayring","year":"2004","journal-title":"A companion to qualitative research"},{"key":"2021080220111619300_keab237-B29","first-page":"e1","article-title":"What is eHealth?: a systematic review of published definitions","volume":"7","author":"Oh","year":"2005","journal-title":"J Med Intern Res"},{"key":"2021080220111619300_keab237-B30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/13607860701366434","article-title":"Mapping the maze of terms and definitions in dementia-related wandering","volume":"11","author":"Algase","year":"2007","journal-title":"Aging Mental Health"},{"key":"2021080220111619300_keab237-B31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/135581960501000110","article-title":"Synthesising qualitative and quantitative evidence: a review of possible methods","volume":"10","author":"Dixon-Woods","year":"2005","journal-title":"J Health Serv Res Policy"},{"key":"2021080220111619300_keab237-B32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","article-title":"A typology of reviews: an analysis of 14 review types and associated methodologies","volume":"26","author":"Grant","year":"2009","journal-title":"Health Info Libr J"},{"key":"2021080220111619300_keab237-B33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jad.2016.10.019","article-title":"The 52 symptoms of major depression: lack of content overlap among seven common depression scales","volume":"208","author":"Fried","year":"2017","journal-title":"J Affect Disord"},{"key":"2021080220111619300_keab237-B34","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1177\/1049732302238251","article-title":"Appraising the evidence: reviewing disparate data systematically","volume":"12","author":"Hawker","year":"2002","journal-title":"Qual Health Res"},{"key":"2021080220111619300_keab237-B35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/phr02020","article-title":"Crime, fear of crime and mental health: synthesis of theory and systematic reviews of interventions and qualitative evidence. Appendix 5, Quality assessment for the systematic review of qualitative evidence","volume":"2","author":"Lorenc","year":"2014","journal-title":"Public Health Res"},{"key":"2021080220111619300_keab237-B36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"2021080220111619300_keab237-B37","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"35","author":"Fransen","year":"2009","journal-title":"Rheum Dis Clin N Am"},{"key":"2021080220111619300_keab237-B38","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score","volume":"49","author":"van der Heijde","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B39","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021080220111619300_keab237-B40","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"2021080220111619300_keab237-B41","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2021080220111619300_keab237-B42","first-page":"789","article-title":"Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis","volume":"33","author":"Wallace","year":"2006","journal-title":"J Rheumatol"},{"key":"2021080220111619300_keab237-B43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"2021080220111619300_keab237-B44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/rheumatology\/keu488","article-title":"Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab","volume":"54","author":"Wright","year":"2015","journal-title":"Rheumatology"},{"key":"2021080220111619300_keab237-B45","doi-asserted-by":"crossref","first-page":"E65","DOI":"10.1111\/j.1399-3046.2009.01129.x","article-title":"Long-term response of juvenile idiopathic arthritis after conditioning with 8 Gy total body irradiation followed by autologous peripheral blood stem cells: case report","volume":"14","author":"Woolfrey","year":"2010","journal-title":"Pediatr Transplant"},{"key":"2021080220111619300_keab237-B46","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1007\/s00296-011-2124-3","article-title":"Repeat etanercept administration restores clinical response of patients with rheumatoid arthritis","volume":"32","author":"Wakabayashi","year":"2012","journal-title":"Rheumatol Int"},{"key":"2021080220111619300_keab237-B47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/art.20859","article-title":"Reduction of joint damage in severe rheumatoid arthritis by high-dose chemotherapy and autologous stem cell transplantation","volume":"52","author":"Verburg","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021080220111619300_keab237-B48","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/ard.2004.034793","article-title":"High dose chemotherapy and syngeneic stem cell transplantation in a patient with refractory rheumatoid arthritis: poor response associated with persistence of host autoantibodies and synovial abnormalities","volume":"64","author":"van Oosterhout","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B49","first-page":"25","article-title":"Intensive immunosuppression and autologous stem cell transplantation for patients with severe rheumatoid arthritis: the Leiden experience","volume":"64","author":"van Laar","year":"2001","journal-title":"J Rheumatol"},{"key":"2021080220111619300_keab237-B50","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021080220111619300_keab237-B51","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/ard.2008.100438","article-title":"Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies","volume":"68","author":"Teng","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B52","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1007\/s00296-011-2200-8","article-title":"Midterm clinico-radiologic findings of an open label observation study of add-on tacrolimus with biologics or non-biologic DMARDs","volume":"32","author":"Takakubo","year":"2012","journal-title":"Rheumatol Int"},{"key":"2021080220111619300_keab237-B53","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/rheumatology\/kez157","article-title":"Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients","volume":"58","author":"Swart","year":"2019","journal-title":"Rheumatology"},{"key":"2021080220111619300_keab237-B54","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3899\/jrheum.150308","article-title":"Magnetic resonance imaging findings following intraarticular infliximab therapy for refractory temporomandibular joint arthritis among children with juvenile idiopathic arthritis","volume":"42","author":"Stoll","year":"2015","journal-title":"J Rheumatol"},{"key":"2021080220111619300_keab237-B55","doi-asserted-by":"crossref","first-page":"A890","DOI":"10.1136\/annrheumdis-2013-eular.2657","article-title":"AB0335 Tocilizumab is effective for the treatment of anti-TNF-and rituximab-refractory rheumatoid arthritis","volume":"72","author":"Reddy","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41927-018-0010-2","article-title":"A phase II trial protocol of tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)","volume":"2","author":"Ramanan","year":"2018","journal-title":"BMC Rheumatol"},{"issue":"Suppl 10","key":"2021080220111619300_keab237-B57","article-title":"Assessment of pain relief with baricitinib by treatment history in patients with refractory rheumatoid arthritis","volume":"70","author":"Pope","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 3","key":"2021080220111619300_keab237-B58","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/annrheumdis-2012-eular.1158","article-title":"AB1160 Golimumab in 25 young adults affected by juvenile idiopathic arthritis (JIA) non responders to other biological agents: preliminary data","volume":"71","author":"Pontikaki","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B59","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/03007995.2019.1688271","article-title":"Real-world treatment persistence of non-tumor necrosis factor inhibitors versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis in South Korea","volume":"36","author":"Park","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 2","key":"2021080220111619300_keab237-B60","first-page":"117","article-title":"OP0133 Unacceptable, refractory pain despite inflammation control in early rheumatoid arthritis and its relation to treatment strategy: results from the randomised controlled Swefot trial","volume":"77","author":"Olofsson","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B61","year":"2013"},{"issue":"Suppl 10","key":"2021080220111619300_keab237-B62","article-title":"Non-surgical periodontal therapy plus short-term antibiotic treatment may improve clinical disease activity: a pilot study in difficult to treat rheumatoid arthritis","volume":"70","author":"Moeller","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021080220111619300_keab237-B63","doi-asserted-by":"crossref","first-page":"170","DOI":"10.31138\/mjr.29.3.170","article-title":"Canakinumab for refractory RA: a case report","volume":"29","author":"Marketos","year":"2018","journal-title":"Mediterr J Rheumatol"},{"key":"2021080220111619300_keab237-B64","first-page":"916","article-title":"Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis","volume":"23","author":"Marchesoni","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2021080220111619300_keab237-B65","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/annrheumdis-2012-eular.1609","article-title":"SP0134 Refractory rheumatoid arthritis; all the therapeutic arrows spent?","volume":"71","author":"Malaviya","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B66","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10067-011-1816-0","article-title":"Allogeneic mesenchymal stem cells transplantation in patients with refractory RA","volume":"31","author":"Liang","year":"2012","journal-title":"Clin Rheumatol"},{"key":"2021080220111619300_keab237-B67","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/rheumatology\/kel301","article-title":"Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab","volume":"45","author":"Kuek","year":"2006","journal-title":"Rheumatology"},{"key":"2021080220111619300_keab237-B68","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3899\/jrheum.090160","article-title":"Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-\u03b1-blocking agents","volume":"36","author":"Koumakis","year":"2009","journal-title":"J Rheumatol"},{"key":"2021080220111619300_keab237-B69","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00296-014-3112-1","article-title":"Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers","volume":"35","author":"Klimiuk","year":"2015","journal-title":"Rheumatol Int"},{"key":"2021080220111619300_keab237-B70","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3109\/s10165-009-0235-4","article-title":"Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics","volume":"20","author":"Kawashiri","year":"2010","journal-title":"Mod Rheumatol"},{"key":"2021080220111619300_keab237-B71","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10067-009-1162-7","article-title":"Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and\/or infliximab","volume":"28","author":"Katsicas","year":"2009","journal-title":"Clin Rheumatol"},{"key":"2021080220111619300_keab237-B72","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/rheumatology\/kel453","article-title":"Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience","volume":"46","author":"Jois","year":"2007","journal-title":"Rheumatology"},{"issue":"Suppl 3","key":"2021080220111619300_keab237-B73","doi-asserted-by":"crossref","first-page":"kez109.080","DOI":"10.1093\/rheumatology\/kez109.080","article-title":"I081 Approach to therapy in refractory rheumatoid arthritis","volume":"58","author":"Isaacs","year":"2019","journal-title":"Rheumatology"},{"key":"2021080220111619300_keab237-B74","doi-asserted-by":"crossref","first-page":"key273.055","DOI":"10.1093\/rheumatology\/key273.055","article-title":"R05 Biologic refractory disease in a cohort study of children and young people with juvenile idiopathic arthritis from the United Kingdom","volume":"57","author":"Heaf","year":"2018","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"2021080220111619300_keab237-B75","doi-asserted-by":"crossref","first-page":"i65","DOI":"10.1093\/rheumatology\/keu096.026","article-title":"26. Refractory rheumatoid arthritis with interstitial lung disease: could abatacept be the answer?","volume":"53","author":"Hayes","year":"2014","journal-title":"Rheumatology"},{"key":"2021080220111619300_keab237-B76","first-page":"69","article-title":"Late-onset neutropaenia after rituximab therapy in rheumatoid arthritis patients. Scand J Rheumatol","author":"Hashmi","year":"2012"},{"issue":"Suppl 3","key":"2021080220111619300_keab237-B77","article-title":"115. Cerebral toxoplasmosis in a RA patient receiving biologic therapy","volume":"58","author":"Gomez","year":"2019","journal-title":"Rheumatology"},{"key":"2021080220111619300_keab237-B78","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/OARRR.S131046","article-title":"Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action","volume":"9","author":"Gillis","year":"2017","journal-title":"Open Access Rheumatol"},{"key":"2021080220111619300_keab237-B79","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"issue":"Suppl 10","key":"2021080220111619300_keab237-B80","article-title":"Neurostimulation for treatment of drug refractory rheumatoid arthritis: a first-in-human study using a novel vagus nerve stimulator","volume":"71","author":"Gaylis","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021080220111619300_keab237-B81","first-page":"981","article-title":"SAT0239 Rapid response with upadacitinib treatment in patients with rheumatoid arthritis and an inadequate response to csDMARDs or bDMARDS","volume":"77","author":"FitzGerald","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B82","doi-asserted-by":"crossref","first-page":"kez106.088","DOI":"10.1093\/rheumatology\/kez106.088","article-title":"089 Single centre cohort of refractory rheumatoid arthritis also identifies a rare subgroup of multiple targeted therapy class non-response","volume":"58","author":"Fitton","year":"2019","journal-title":"Rheumatology"},{"key":"2021080220111619300_keab237-B83","first-page":"443","article-title":"THU0627 Treatment of rheumatoid arthritis: adherence to guidelines in private practice","volume":"76","author":"Fernandes","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B84","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/annrheumdis-2016-eular.4452","article-title":"SAT0183 Long-Term efficacy, safety, and tolerability of tocilizumab in rituximab-refractory rheumatoid arthritis","volume":"75","author":"Farah","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B85","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/07853890310001339","article-title":"Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases","volume":"35","author":"Eklund","year":"2003","journal-title":"Ann Med"},{"key":"2021080220111619300_keab237-B86","first-page":"S43","article-title":"5-year follow up of abatacept therapy for systemic sclerosis with chronic arthritis","volume":"32","author":"Di Poi","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2021080220111619300_keab237-B87","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/0394632015593220","article-title":"Safety and efficacy of intra-articular anti-tumor necrosis factor \u03b1 agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare","volume":"29","author":"Carubbi","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2021080220111619300_keab237-B88","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/ard.2005.051169","article-title":"Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor \u03b1 agents: an open-label observational study","volume":"65","author":"Brulhart","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B89","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2217\/ijr.15.42","article-title":"Adrenocorticotropic hormone gel in patients with refractory rheumatoid arthritis: a case series","volume":"10","author":"Brown","year":"2015","journal-title":"Int J Clin Rheumatol"},{"key":"2021080220111619300_keab237-B90","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1002\/1529-0131(199911)42:11<2275::AID-ANR3>3.0.CO;2-6","article-title":"Intensified-dose (4 gm\/m2) cyclophosphamide and granulocyte colony-stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis","volume":"42","author":"Breban","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2021080220111619300_keab237-B91","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00296-015-3231-3","article-title":"Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus","volume":"35","author":"Bou","year":"2015","journal-title":"Rheumatol Int"},{"issue":"Suppl 10","key":"2021080220111619300_keab237-B92","article-title":"Application of combined reporting of benefit and harm (OMERACT 3\u2009\u00d7\u20093 methodology) to the rheumatoid arthritis comparison of active therapies trial","volume":"67","author":"Boers","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2021080220111619300_keab237-B93","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40272-016-0186-0","article-title":"Management of juvenile idiopathic arthritis: a clinical guide","volume":"18","author":"Blazina","year":"2016","journal-title":"Paediatr Drugs"},{"key":"2021080220111619300_keab237-B94","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2021080220111619300_keab237-B95","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.semarthrit.2019.02.004","article-title":"Risk profiling for a refractory course of rheumatoid arthritis","volume":"49","author":"Becede","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2021080220111619300_keab237-B96","doi-asserted-by":"crossref","first-page":"A853.2","DOI":"10.1136\/annrheumdis-2013-eular.2541","article-title":"AB0218 Addressing cardiovascular risk in treatment resistant RA","volume":"72","author":"Baxter","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B97","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/injr.injr_37_18","article-title":"Safety and efficacy of abatacept among patients with refractory rheumatoid arthritis: experience from a North Indian tertiary care hospital","volume":"13","author":"Arjun","year":"2018","journal-title":"Indian J Rheumatol"},{"key":"2021080220111619300_keab237-B98","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial","volume":"76","author":"\u00c1lvaro-Gracia","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"2021080220111619300_keab237-B99","article-title":"Rheumatoid arthritis patients resistant to biologic therapy, are they different?","volume":"69","author":"Al-Herz","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2021080220111619300_keab237-B100","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/annrheumdis-2013-204466","article-title":"Genetic variation in VTCN1 (B7-H4) is associated with course of disease in juvenile idiopathic arthritis","volume":"73","author":"Albers","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B101","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3201\/eid2210.151245","article-title":"Infection-related death among persons with refractory juvenile idiopathic arthritis","volume":"22","author":"Abinun","year":"2016","journal-title":"Emerg Infect Dis J"},{"key":"2021080220111619300_keab237-B102","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1136\/annrheumdis-2014-205302","article-title":"Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3899\/jrheum.080591","article-title":"Proposed metrics for the determination of rheumatoid arthritis outcome and treatment success and failure","volume":"36","author":"Wolfe","year":"2009","journal-title":"J Rheumatol"},{"key":"2021080220111619300_keab237-B104","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/acr.20132","article-title":"Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis","volume":"62","author":"Barton","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2021080220111619300_keab237-B105","first-page":"880","article-title":"Rheumatology outcomes: the patient\u2019s perspective","volume":"30","author":"Carr","year":"2003","journal-title":"J Rheumatol"},{"key":"2021080220111619300_keab237-B106","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/annrheumdis-2016-209835","article-title":"The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission","volume":"76","author":"van Tuyl","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B107","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3899\/jrheum.141113","article-title":"Remission in rheumatoid arthritis: working toward incorporation of the patient perspective at OMERACT 12","volume":"43","author":"van Tuyl","year":"2016","journal-title":"J Rheumatol"},{"key":"2021080220111619300_keab237-B108","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/ard.2010.135129","article-title":"European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects","volume":"70","author":"de Wit","year":"2011","journal-title":"Ann Rheumat Dis"},{"key":"2021080220111619300_keab237-B109","doi-asserted-by":"crossref","first-page":"e000129","DOI":"10.1136\/rmdopen-2015-000129","article-title":"Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatology","volume":"1","author":"de Wit","year":"2015","journal-title":"RMD Open"},{"key":"2021080220111619300_keab237-B110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/annrheumdis-2017-212141","article-title":"Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research","volume":"77","author":"McCann","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B111","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.181094","article-title":"Consensus building in OMERACT: recommendations for use of the Delphi for Core Outcome Set development","volume":"46","author":"Humphrey-Murto","year":"2019","journal-title":"J Rheumatol"},{"key":"2021080220111619300_keab237-B112","doi-asserted-by":"crossref","first-page":"vi5","DOI":"10.1093\/rheumatology\/kes279","article-title":"ACR\/EULAR 2010 rheumatoid arthritis classification criteria","volume":"51","author":"Kay","year":"2012","journal-title":"Rheumatology"},{"key":"2021080220111619300_keab237-B113","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/annrheumdis-2013-204948","article-title":"Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology","volume":"74","author":"Buch","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B114","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2217\/npy.11.35","article-title":"Treatment-refractory schizophrenia: what is it and what has been done about it?","volume":"1","author":"Citrome","year":"2011","journal-title":"Neuropsychiatry"},{"key":"2021080220111619300_keab237-B115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2377-12-29","article-title":"Towards a definition of refractory neuropathic pain for epidemiological research. An international Delphi survey of experts","volume":"12","author":"Smith","year":"2012","journal-title":"BMC Neurol"},{"key":"2021080220111619300_keab237-B116","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.epilep.2013.01.001","article-title":"Pharmacoresistant epilepsy: definition and explanation","volume":"1","author":"Alexopoulos","year":"2013","journal-title":"Epileptology"},{"key":"2021080220111619300_keab237-B117","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1183\/09031936.93.06050743","article-title":"Steroid resistant asthma: what is the clinical definition?","volume":"6","author":"Woolcock","year":"1993","journal-title":"Eur Respir J"},{"key":"2021080220111619300_keab237-B118","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2011.04.027","article-title":"Refractory disease in systemic lupus erythematosus","volume":"10","author":"Campar","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2021080220111619300_keab237-B119","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/BOR.0b013e32835264f4","article-title":"Changing winds in refractory autoimmune disease in children: clearing the road for tolerance with cellular therapies","volume":"24","author":"Swart","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"2021080220111619300_keab237-B120","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/art.40844","article-title":"Further considerations of the need for integrated mental health treatment in rheumatoid arthritis patients: comment on the review by Matcham et al","volume":"71","author":"Zembrzuska","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021080220111619300_keab237-B121","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez110.065"},{"key":"2021080220111619300_keab237-B122","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2013-203302","article-title":"Biologic discontinuation studies: a systematic review of methods","volume":"73","author":"Yoshida","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021080220111619300_keab237-B123","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab237\/38869387\/keab237.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3540\/39543796\/keab237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3540\/39543796\/keab237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:07:42Z","timestamp":1671581262000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/8\/3540\/6169014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":123,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,3,12]]},"published-print":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab237","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,3,12]]}}}